Inclusion of diprotonated [2.2.2]cryptand in the cavity of uranyl-complexed p-phenyltetrahomodioxacalix[4]arene.
In the title compound, 4,7,13,16,21,24-hexaoxa-1,10-diazoniabicyclo[8.8.8]hexacosane dioxo[7,13,21,27-tetraphenyl-3,17-dioxapentacyclo[23.3.1.1(5,9).1(11,15).1(19,23)]ditriaconta-1(29),5,7,9(30),11(31),12,14,19(32),20,22,25,27-dodecaene-29,30,31,32-tetraolato]uranium dimethyl sulfoxide trisolvate, (C(18)H(38)N(2)O(6))[U(C(54)H(40)O(6))O(2)].3C(2)H(6)OS, the uranyl ion is bound to the four phenoxide groups of the deprotonated p-phenyltetrahomodioxacalix[4]arene ligand in a cone conformation, resulting in a dianionic complex. The diprotonated [2.2.2]cryptand counter-ion is located in the cavity defined by the eight aromatic rings of the homooxacalixarene, where it is held by cation-anion, cation-pi and possibly C-H...pi interactions. Dimerization in the packing leads to the formation of sandwich assemblages in which two diprotonated [2.2.2]cryptands are encompassed by two uranyl complexes.